# Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

> **NCT02772276** · PHASE2 · COMPLETED · sponsor: **MediBeacon** · enrollment: 234 (actual)

## Conditions studied

- Acute Kidney Injury

## Interventions

- **DRUG:** MB-102-- single dose of 4 µmol/kg
- **DRUG:** MB-102-- single dose of 130 mg
- **DRUG:** MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart
- **DRUG:** MB-102-- two doses of 130 mg 24 hours apart
- **DRUG:** Iohexol
- **DEVICE:** QuantumLeap
- **DEVICE:** Radiance
- **DEVICE:** Brilliance (1 or 2 sensors)
- **DEVICE:** Brilliance (2-part sensor)

## Key facts

- **NCT ID:** NCT02772276
- **Lead sponsor:** MediBeacon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-11
- **Primary completion:** 2021-08-04
- **Final completion:** 2021-08-04
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02772276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02772276, "Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02772276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*